321 results about "Cognitive impairment" patented technology

The application discloses a kind of cognitive impairment early screening and diagnosis system based on multi-modal data, including following module: (1) multi-modal data acquisition module, for obtaining image data, gene data, behavior data and clinical narrative information;The clinical narrative information includes at least two kinds of patient complaint text, interference factor hook item, symptom time axis;(2) causal purification module, for filtering the pseudo-correlation between multi-modal data by clinical narrative anchoring and reverse intervention deduction, including: narrative anchoring unit: based on preset causal conflict rule base, through structured clinical narrative field identification data conflict, trigger freezing or weight reduction operation;Intervention deduction unit: generate the reverse intervention verification package containing low-cost intervention measures and review plan, and update causal rule base based on review data;The application breaks through the statistical correlation limitation of traditional technology, realizes the upgrade of diagnosis and treatment paradigm from "correlation" to "causality".

The invention discloses a cognitive impairment risk intelligent matching intervention system based on multi-modal data, and belongs to the technical field of cognitive impairment, and the cognitive impairment risk intelligent matching intervention system specifically comprises the following steps: collecting a tactile interaction sequence and a face video data stream when a user executes a cognitive intervention task, and constructing an original multi-modal data set; extracting tactile operation track features and reconstructing a heart rate variability sequence, and generating a synchronous multi-mode feature set; identifying a difference interval of state fluctuation and extracting behavior and physiological features in the interval to form an instant physical and mental load parameter set; in combination with an interaction efficiency index in the task execution record, generating a joint state feature vector, and outputting a personalized adaptation instruction through a pre-trained sub-state-parameter association model; and constructing an adaptive strategy model by using the multi-modal features and an adaptive instruction to realize millisecond-level dynamic adjustment from the real-time multi-modal features to task parameters. According to the method, real-time perception and accurate matching of the cognitive emotion load of the user are realized, and the individuation degree and instantaneity of intervention are improved.

The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.

The invention discloses a cross-crowd wearable ECG emotion recognition method based on a hybrid convolution-Mama network. The method comprises the following steps: S1, constructing a multimedia emotion induction experiment normal form for old people and cognitive impairment groups, and collecting wearable ECG data; s2, the collected original electrocardiosignals are subjected to standardization preprocessing; s3, constructing a hierarchical scale perception convolution module to perform multi-scale morphological feature extraction on the preprocessed electrocardiogram data; s4, performing physiological baseline remodeling on the feature map by using a non-local channel convolution attention mechanism; s5, constructing a bidirectional state space model based on a Mamba2 architecture, and carrying out long-time-history time sequence dependence modeling; and S6, fusing the spatio-temporal features to carry out emotion category probability prediction and implement personalized model fine tuning. According to the method, core challenges in ECG emotion recognition can be successfully solved, and a complete processing link from multi-dimensional sensing of signals to individualized noise filtering to efficient context understanding is constructed.

The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.

The invention relates to the technical field of smart pension and health information, and discloses a virtual reality-based intelligent activity interaction method for elderly groups, which comprises the following steps: S1, information acquisition: acquiring health basic information, activity preference information and virtual reality equipment use proficiency information of elderly users, and forming a user basic portrait; a safety data interface connected with a health record system is constructed, detailed health basic information of elderly users is integrated, and multi-dimensional adaptability constraint conditions including activity intensity, action complexity, scene acousto-optic stimulation, activity duration and the like are automatically constructed according to the detailed health basic information; according to the mechanism, activity items with controllable safety risks can be intelligently screened and marked for old people with different health conditions such as cardiovascular diseases, limb disorders, sensory decline and cognitive impairment, so that the potential safety hazard caused by one-step operation of traditional activities is fundamentally solved, and the safety of intervened footstones is ensured.

The invention relates to the technical field of biological medicines, in particular to application of Amomum villosum Lour. In preparation of products for preventing and / or improving symptoms related to obesity and glucose and lipid metabolism disorder. The symptoms comprise hyperglycemia level, cardiovascular and cerebrovascular diseases, cognitive impairment and the like. The result shows that the fructus amomi can effectively reduce the blood sugar level, obviously inhibit the rise of low-density lipoprotein, improve the cognitive function and regulate the lipid metabolism balance. Based on good glycolipid metabolism regulation activity, fructus amomi can be used for improving hyperglycemia, cardiovascular and cerebrovascular diseases, related cognitive function decline and other symptoms caused by abnormal glycolipid metabolism.

The invention belongs to the technical field of biological medicine, and relates to application of a compound D25, in particular to application of a small molecule compound D25 in preparation of a product for preventing or treating Alzheimer's disease (AD), and the structural formula of the compound is shown in the specification. Experiments prove that the small molecule compound D25 can pass through a blood brain barrier, can induce autophagy, can relieve pathological characteristics of an AD mouse model and improve cognitive impairment of the AD mouse model, can reduce the proportion of disease-related microglial cells by recovering the morphology of the microglial cells and improving the A beta phagocytosis capacity of the microglial cells, has the potential of promoting neuronal growth and increasing the number of protrusions, and can be used for preparing a medicine for treating the disease-related microglial cells. Therefore, AD can be effectively treated, the safety is high, the effect is achieved, and the application prospect is great.

The present invention relates to a health management system based on cognitive impairment rehabilitation content, and more specifically, to a health management system based on cognitive impairment rehabilitation content that identifies the degree and grade of individual cognitive impairment based on individual biosignals and provides personalized cognitive impairment rehabilitation content corresponding thereto, thereby moving away from conventional uniform educational methods and providing personalized content optimized for each individual, which not only enhances interest and immersion in cognitive impairment rehabilitation content but also further improves the efficiency of cognitive function rehabilitation.

The invention belongs to the field of intelligent medical treatment. The invention provides a two-channel feature screening method for cognitive impairment recognition modeling and a modeling method thereof, and the method comprises the steps: taking multi-site cognitive impairment screening data as input data, and carrying out the preprocessing of the input data; constructing a traditional robust feature screening channel and an LLM knowledge enhancement screening channel, and performing feature screening on the preprocessed input data; integrating dual-channel feature screening results, performing bias perception joint score optimization, and obtaining a feature set; and performing semantic alignment and version normalization on the feature set to obtain a high-quality feature set. And applying the high-quality feature set to a classifier for cognitive impairment recognition modeling, and generating a clinical decision support result. According to the parallel feature screening method based on combination of a large language model and traditional feature screening, the problem of data heterogeneity bias in cognitive impairment recognition is systematically solved by constructing a dual-channel collaborative feature evaluation architecture, and organic unification of statistical robustness and clinical interpretability is achieved.

To provide a pharmaceutical composition for preventing or treating cognitive dysfunction.SOLUTION: The pharmaceutical composition contains benzoic acid or a benzoic acid salt.SELECTED DRAWING: None

The invention belongs to the technical field of biological medicine, and discloses a pharmaceutical composition for treating metabolic diseases, a preparation method and application, and the pharmaceutical composition comprises edaravone or pharmaceutically acceptable salts thereof and dextroborneol. The weight ratio of the edaravone to the dextroborneol is (10: 1)-(1: 1). The invention finds that the combination of edaravone and dextroborneol shows remarkable curative effects in the aspects of improving cognitive function, reducing blood fat, relieving fatty liver and recovering cardiac function and / or overall metabolic homeostasis; meanwhile, the pharmaceutical composition disclosed by the invention has a remarkable comprehensive treatment effect on metabolic diseases or complications (such as metabolic syndrome) of the metabolic diseases and / or vascular cognitive impairment complicated with the metabolic syndrome.

The invention discloses armillariella mycelium polysaccharide ATMP capable of improving cognitive impairment and a preparation method and application of the armillariella mycelium polysaccharide ATMP. The polysaccharide is composed of two components, and the molecular weights of the two components are 2.30 * 10 < 4 > Da and 4.56 * 10 < 5 > Da respectively; the monosaccharide composition comprises mannose (Man), glucose (Glc) and galactose (Gal), and the molar ratio of the mannose (Man) to the glucose (Glc) to the galactose (Gal) is 1: 16.64: 1.96. Animal experiment results show that the armillariella mycelium polysaccharide ATMP can improve cognitive impairment induced by lipopolysaccharide (LPS) by improving the spatial memory ability of mice, repairing the disorder state and deletion injury of neurons in a hippocampal region and relieving neuroinflammatory response, so that the obvious neuroprotective effect is achieved. As a natural brain-benefiting active component, the armillariella tabescens mycelium polysaccharide ATMP has a wide application prospect in the related fields of brain health.

The present application relates to the technical field of probiotics, and particularly relates to a Bifidobacterium breve strain and application of the Bifidobacterium breve strain in prevention or treatment of neurodegenerative diseases and neuroinflammation related to neurodegenerative diseases. Bifidobacterium breve ) BKR006, which is preserved in the China General Microbiological Culture Collection Center (CGMCC) (address: No. 1, Xili Beichen, Chaoyang District, Beijing), and the preservation number is CGMCC No. 36096. The strain in the present application is proved in animal experiments that the strain can not only significantly improve the cognitive function and A beta pathology of AD model animals, but also effectively inhibit neuroinflammation in PD models and improve related cognitive impairment, and has a broad spectrum of neuroprotective effect and good development and application prospect.

The application discloses application of T1R3 agonist sucralose in relieving Alzheimer's disease and related cognitive impairment, and aims at brain glucose metabolism disorder and cognitive decline problem, and the application takes sucralose as the only pharmaceutical active ingredient, corrects brain glucose metabolism disorder through targeting brain astrocyte sweet taste receptor T1R3, and then treats and relieves neurodegenerative diseases. The application is proved by animal experiments that cognitive dysfunction of AD model mice can be improved in a full range of molecular mechanisms, cell functions, tissue metabolisms and whole behavior, and a variety of dosage forms and medication strategies can be selected, and the application has good in-vivo safety and clinical transformation potential.

A computer-implemented method, system, and computer program product for assessing and enhancing safety and functionality of environments for aging populations. A description of the physical characteristics of an environment (e.g., aging and senior care environments) is received. Such a description includes a comprehensive set of quantifiable and observable data points that define the physical, sensory, and spatial attributes of the space of the environment. Upon receiving the description of physical characteristics of an environment, the description is analyzed against a set of environment design rules (structured guidelines and criteria used to systematically arrange, specify, or modify physical and spatial characteristics of the environment to optimize its safety, functionality, accessibility, and psychological impact for a specified group) tailored for aging populations and individuals with cognitive impairment. Upon performing such an analysis, one or more recommendations for modifying the environment are then generated based on the analysis.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The present invention relates to a donepezil and tadalafil combination therapy for the prevention, treatment or amelioration of Alzheimer's disease or cognitive dysfunction. The combined administration of donepezil and tadalafil according to the present invention has an improvement effect on Alzheimer's disease or cognitive impairment superior to that of the individual administration of donepezil, and thus can be effectively used as a therapeutic or complexing agent or the like for Alzheimer's disease or cognitive impairment.

This invention relates to the field of cognitive health companionship technology, specifically to a multimodal companionship system for patients with cognitive impairment based on AI technology. The invention receives memory materials from a family member's terminal, constructs an interactive virtual scene, configures guiding questions, records the patient's answers to all guiding questions, sets the initial difficulty level of cognitive training based on an assessed memory recall integrity score, and collects performance data after the patient completes cognitive training tasks to determine if the initial difficulty level needs adjustment. This achieves precise matching of cognitive training difficulty to the patient's current cognitive level. Simultaneously, based on the performance data of cognitive training tasks within a subsequently set training period, a cognitive ability report is generated and compared with historical cognitive ability reports in multiple dimensions to assess the patient's cognitive ability improvement. This reflects the dynamic changes and improvement trajectory of the patient's cognitive ability, effectively improving the targeting and effectiveness of cognitive training.

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.

The application discloses application of a Fructus Mume pill in preparation of a medicine for treating diabetic encephalopathy, and finds that there is a clear correlation between the Fructus Mume pill and the diabetic encephalopathy. Research results show that the Fructus Mume pill can improve the abnormal metabolic state of a diabetic model mouse, reduce learning and memory dysfunction and cognitive impairment under a diabetic state, and has a good prevention and treatment effect on the diabetic encephalopathy. The application clearly defines the pharmacological effect of the Fructus Mume pill in preventing and treating the diabetic encephalopathy and a possible action mechanism, and provides an experimental basis for TCM intervention on the diabetic encephalopathy. The application provides a new train of thought for research and development of a medicine related to the diabetic encephalopathy, and has a good application prospect.

The invention relates to an application of propylamine bromide (C23H30BrNO3) in the treatment of sleep disorder, in particular to an application of propylamine bromide (C23H30BrNO3) in the treatment of sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, so that long-term use of the traditional sleep drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely propylamine bromide, in preparation of drugs for treating sleep disorders is provided for the first time, especially those which are insensitive to existing sedative drugs or related to circadian rhythm disorder, and have no toxic or side effects on sleep disorders. The optimal curative effect can be achieved in the indications by 20 mu M, the sleep-awakening cycle disorder caused by PER3 defects is improved, and the normal sleep-awakening cycle is recovered.

The invention provides an augmented reality postoperative cognitive impairment risk prediction method and system, and relates to the technical field of wisdom medical treatment, and the prediction method comprises the steps: obtaining medical monitoring data and an AR interaction behavior type corresponding to a feasibility label, and inputting the AR interaction behavior type into a pre-trained XGboost model when it is determined that the cognitive function is allowed to be evaluated according to the feasibility label, determining a target AR scene in the multiple types of AR test scenes; acquiring test data of the patient in the target AR scene, wherein the test data comprises equipment position information of the image acquisition equipment, a test picture tested by the patient and AR behavior interaction data; picture features of a test picture are recognized through an image recognition module, equipment position information is mapped through a linear transformation layer and activated through a rectification linear unit, a view angle weight vector matched with picture feature channel dimensions is generated, and the view angle weight vector and the picture features are fused to obtain calibrated picture features.

The invention provides a traditional Chinese medicine preparation for improving or treating cognitive impairment, and relates to the technical field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine preparation is prepared from morinda officinalis, eclipta, semen boitae, fructus alpiniae oxyphyllae, bighead atractylodes rhizome, valerian, turmeric, rhizoma acori graminei, leech, rhizoma anemarrhenae, dendrobium officinale, endothelium corneum gigeriae galli, hematoxylon and honey-fried licorice root. The traditional Chinese medicine preparation shows remarkable neuroprotection and cognition improvement effects on the cell level and the animal level, in the cell level, the preparation can effectively resist Abeta1-42 induced cell damage, and the protection effect is achieved through multiple ways of improving the cell activity, enhancing the oxidation resistance, inhibiting neuroinflammation and the like; in animal experiments, the preparation can comprehensively improve cognitive impairment of APP / PS1 model mice, including relieving behavioral abnormality, improving spatial learning and memory ability, enhancing new object recognition ability, and effectively reducing deposition of A beta in hippocampus on a molecular level. The invention provides a new thought for improving or treating cognitive impairment.

The application discloses application of PTN in preparation of products for treating cognitive impairment caused by severe infection. The inhibitor of PTN provided by the application can inhibit chronic neuroinflammation, thereby preventing and inhibiting formation and development of late cognitive impairment caused by severe infection, and meanwhile, inhibition of expression or function of PTN can effectively block damage of infiltrating macrophages to microglia cells, thereby providing a new direction for treatment of related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for improving a cognitive function as well as a preparation method, a product and application of the composition. The composition is prepared by taking soybean meal, whey protein peptide powder and bovine bone collagen peptide powder in a mass ratio of 1: 3: 2 as peptide source raw materials, matching the peptide source raw materials with AMY001, lactobacillus plantarum LP-90 and clostridium butyricum (3: 1: 1) compound strains, and carrying out enzyme production self-hydrolysis by bacillus amyloliquefaciens, peptide-bacterium anaerobic synergistic fermentation and sodium alginate-HPMC-CPP composite carrier embedding. According to the present invention, the hippocampus Abeta1-42 protein can be cleared, the BDNF content can be increased, the IL-6 expression inhibition multi-mechanism synergistic effect can be achieved, the memory improvement rate and the Abeta1-42 clearance rate are high, and the cognitive impairment can be significantly repaired. The composition is high in stability and bioavailability, controllable in preparation process and suitable for development of food and health care products for improving the cognitive function and medicines for preventing or assisting in improving diseases related to cognitive impairment.

The invention relates to the technical field of data processing, and discloses a vascular cognitive impairment assessment method and device, electronic equipment and a storage medium, and the method comprises the steps: obtaining diffusion tensor imaging data of a target object; calculating a target diffusion tensor parameter based on the diffusion tensor imaging data, and generating a target diffusion tensor parameter diagram; inputting the target diffusion tensor parameter map into a pre-constructed deep learning model to obtain a target significance weight map of the target object; based on the target saliency weight map and a pre-established mutual information atlas set, determining a structural similarity score between the target saliency weight map and each mutual information atlas in the mutual information atlas set; and based on the structural similarity score, determining a cognitive impairment risk level represented by the target neuropsychological scale. According to the method, the dysfunction of the patient in a plurality of cognitive fields can be accurately identified, and personalized cognitive disorder risk level evaluation is provided for each patient.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a traditional Chinese medicine composition in the preparation of drugs for improving cognitive impairment. By weight, the traditional Chinese medicine composition comprises: 225-300 parts rhubarb, 50-75 parts pig bile powder, 90-120 parts aster, 360-480 parts scrophularia, 180-240 parts immature bitter orange peel, and 180-240 parts areca nut. This invention is the first to demonstrate that a composition of six traditional Chinese medicines, including scrophularia, rhubarb, and areca nut, significantly improves memory acquisition (induced by scopolamine), consolidation (induced by sodium nitrite), and retrieval impairments, covering the entire process of memory formation, encoding, storage, and retrieval, thus overcoming the limitations of existing drugs that only target a single memory stage.